NCT06059885View on ClinicalTrials.gov

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

December 20, 2025

Conditions

Liver Neoplasms

Interventions

DRUG

Tislelizumab plus tyrosine kinase inhibitor

Lenvatinib, tyrosine kinase inhibitor (TKIs)

Trial Locations (1)

100039

RECRUITING

302 Hospital, Beijing

All Listed Sponsors

lead

Beijing 302 Hospital

OTHER